Early intervention for psychosis with N-methyl-D-aspartate receptor modulators

Clinical Psychopharmacology and Neuroscience

Volumn 13, Issue 3, 2015, Pages 328-329

  Dong, Chao ^a   Hashimoto, Kenji ^a  

^a CHIBA UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

DEXTRO SERINE; ISOMERASE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; PLACEBO; SERINE RACEMASE; UNCLASSIFIED DRUG;

AMINO ACID BLOOD LEVEL; CEREBROSPINAL FLUID; COGNITIVE DEFECT; CONTROLLED STUDY; EARLY INTERVENTION; GENETIC ASSOCIATION; HUMAN; LETTER; NEGATIVE SYNDROME; NEUROTRANSMISSION; OUTCOME ASSESSMENT; PRODROMAL SYMPTOM; PSYCHOPHARMACOTHERAPY; PSYCHOSIS; TREATMENT DURATION;

EID: 84949478590     PISSN: 17381088     EISSN: 20934327     Source Type: Journal    
DOI: 10.9758/cpn.2015.13.3.328     Document Type: Letter

References (12)

1. Fusar-Poli P, Deste G, Smieskova R, Barlati S, Yung AR, Howes O, et al. Cognitive functioning in prodromal psychosis: a meta-analysis. Arch Gen Psychiatry 2012;69:562-571.
2. Hashimoto K. Targeting of NMDA receptors in new treatments for schizophrenia. Expert Opin Ther Targets 2014;18: 1049-1063.
3. McGorry PD. Early intervention in psychosis: obvious, effective, overdue. J Nerv Ment Dis 2015;203:310-318.
4. Thompson E, Millman ZB, Okuzawa N, Mittal V, DeVylder J, Skadberg T, et al. Evidence-based early interventions for individuals at clinical high risk for psychosis: a review of treatment components. J Nerv Ment Dis 2015;203:342-351.
5. Seidman LJ, Nordentoft M. New targets for prevention of schizophrenia: is it time for interventions in the premorbid phase? Schizophr Bull 2015;41:795-800.
6. Kantrowitz JT, Woods SW, Petkova E, Cornblatt B, Corcoran CM, Chen H, et al. D-serine for the treatment of negative symptoms in individuals at clinical high risk of schizophrenia: a pilot, double-blind, placebo-controlled, randomized parallel group mechanistic proof-of-concept trial. Lancet Psychiatry 2015;2:403-412.
7. Hashimoto K, Fukushima T, Shimizu E, Komatsu N, Watanabe H, Shinoda N, et al. Decreased serum levels of D-serine in patients with schizophrenia: evidence in support of the N-methyl-D-aspartate receptor hypofunction hypothesis of schizophrenia. Arch Gen Psychiatry 2003;60:572-576.
8. Yamada K, Ohnishi T, Hashimoto K, Ohba H, Iwayama-Shigeno Y, Toyoshima M, et al. Identification of multiple serine racemase (SRR) mRNA isoforms and genetic analyses of SRR and DAO in schizophrenia and D-serine levels. Biol Psychiatry 2005;57:1493-1503.
9. Hashimoto K, Engberg G, Shimizu E, Nordin C, Lindström LH, Iyo M. Reduced D-serine to total serine ratio in the cerebrospinal fluid of drug naive schizophrenic patients. Prog Neuropsychopharmacol Biol Psychiatry 2005;29:767-769.
10. Schizophrenia Working Group of the Psychiatric Genomics Consortium. Biological insights from 108 schizophreniaassociated genetic loci. Nature 2014;511:421-427.
11. Hagiwara H, Iyo M, Hashimoto K. Neonatal disruption of serine racemase causes schizophrenia-like behavioral abnormalities in adulthood: clinical rescue by d-serine. PLoS One 2013;8:e62438.
12. Woods SW, Walsh BC, Hawkins KA, Miller TJ, Saksa JR, D'Souza DC, et al. Glycine treatment of the risk syndrome for psychosis: report of two pilot studies. Eur Neuropsychopharmacol 2013;23:931-940.